Pharmaceutical Benefits Scheme

What Pharmaceutical Benefits Scheme does

The Pharmaceutical Benefits Scheme (PBS) is an Australian Government statutory subsidy program established in 1948 under the National Health Act 1948 (consolidated under the National Health Act 1953) and administered by the Department of Health and Aged Care. It subsidises the cost of prescription medicines for all Australian residents holding a Medicare card, operating as the national monopsony buyer of subsidised pharmaceuticals. PBS distributes medicines through a legislatively defined network comprising Section 90 community pharmacies, Section 92 approved medical practitioners, and Section 94 approved hospital authorities, with specialised arrangements under Section 100 of the National Health Act covering Highly Specialised Drugs, Efficient Funding of Chemotherapy, Botulinum Toxin, Growth Hormone, IVF, and Opioid Dependence Treatment.

PBS's product surface includes the A-Z Medicine Listings portal, a Medicine Status tracker for listing pipeline visibility, the PBAC Agenda, monthly Schedule change archives, Streamlined Authority codes, Therapeutic Group premiums (including F1 group premiums), Browse by Prescriber categories (Dental, Midwife, Nurse Practitioner, Optometrical), and the PBS Safety Net. The program also publishes Standard Packs and Prices data and operates a public API plus CSV data feeds via the PBS Software Developers portal (data.pbs.gov.au). The underlying technology is a national medicines subsidy scheme with a centralised PBS Schedule database containing all subsidised medicines, pricing, restrictions, and authority codes.

PBS does not generate revenue; it is funded by the Australian Government. Patients pay statutory co-payments (approximately $25.00 general, approximately $7.70 concession) per prescription, with Safety Net thresholds (approximately $254.30 concession, $1,542.10 general as of 2024) reducing costs to concession rates after thresholds are reached. Brand premiums and therapeutic group premiums are paid by patients who choose higher-priced brands or drugs. A $377.3 million budget commitment over four years from 2023-24 funds the 1 July 2023 transfer of Opioid Dependence Treatment medicines into the Section 100 HSD Program (Community Access) with nationally consistent community pharmacy payment arrangements.

Name

Pharmaceutical Benefits Scheme

Legal name

The Commonwealth of Australia

Website

https://pbs.gov.au

Company type

Private

Founded year

1948

Operating status

Operating

Short description

The Pharmaceutical Benefits Scheme (PBS) is an Australian Government program that subsidises prescription medicines for all Medicare-eligible residents, distributing through community pharmacies, hospitals, and approved prescribers under the National Health Act 1953.

Ownership category

akta.pro rank

Product category

Government Pharmaceutical Subsidy Program

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

SIC

Services-Health Services (8000)

akta.pro primary industry

Group Pharmacy Benefit (Rx) Coverage & PBM-Integrated Plans (FSAIAFAN)

akta.pro secondary industries

Patient Access Programs & Affordability (Copay/Hubs/PSP) (HLAIAKAG), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

Keywords

• Government pharmaceutical subsidy
• Prescription medicine subsidies
• National medicines scheme
• Pharmaceutical benefits administration
• Medicine listings database

GTM type

B2C

Offering type

Services

Cost components

Operations, Technology or R&D

Pricing tiers

Distribution channels5 records

Marketing channels3 records

Core offering

The Pharmaceutical Benefits Scheme provides subsidised prescription medicines to all Australian residents with Medicare eligibility. It maintains the PBS Schedule database containing over 900 subsidised medicines across multiple therapeutic areas, with tiered co-payments, safety net protections, and specialised programs under Section 100 of the National Health Act 1953. The scheme also offers digital infrastructure including the A-Z Medicine Listings portal, Medicine Status tracker, PBS API for developers, and specialised treatment programs including the Highly Specialised Drugs Program and Opioid Dependence Treatment Program.

Product overview

The Pharmaceutical Benefits Scheme (PBS) is an Australian government program that subsidises the cost of a wide range of prescription medicines. The system provides multiple access points including an A-Z Medicine Listings portal for browsing the complete PBS Schedule, a Medicine Status tracker for monitoring drug listing progress, and the PBAC Agenda for committee meeting information. The scheme operates specialized programs under Section 100 of the National Health Act 1953, including the Highly Specialised Drugs Program (with Public Hospital, Private Hospital, and Community Access streams), Efficient Funding of Chemotherapy, Botulinum Toxin Program, Growth Hormone Program, IVF Program, and Opioid Dependence Treatment Program. Additional features include Streamlined Authority for simplified prescribing, Supply Only items in transition, Browse by Therapeutic Group with F1 therapeutic premiums, Browse by Prescriber categories (Dental, Midwife, Nurse Practitioner, Optometrical), the PBS Safety Net Scheme, and Standard Packs and Prices listings. The PBS also provides data access through its API and CSV files for software developers.

Differentiator

Problem solved

Functional benefit

Products and services

• A-Z Medicine Listings

Quantifiable outcome

• Patients pay only $25.00 per prescription (general) or $7.70 (concession) for most PBS medicines, with the Australian Government subsidising the remainder
• +2 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Centers for Medicare & Medicaid Services (CMS) — Medicare Part D: US federal agency administering Medicare Part D, the federal prescription drug benefit covering ~50M Americans. Closest US analog to PBS as a national government prescription-subsidy program, though delivered via competing private PBMs rather than a single in-house administrator.
• CVS Caremark: Pharmacy benefit management arm of CVS Health, providing formulary administration, pharmacy network management, and drug-pricing negotiation for US health plans. Operates the same core activity set as PBS (formulary, pricing, claims) under a commercial model.
• Express Scripts (Evernorth): Largest US pharmacy benefit manager, administering prescription drug benefits for tens of millions of Americans. Performs the same formulary, negotiation, and claims-administration functions as PBS but commercially and at much larger scale; illustrates the private-sector equivalent of PBS's mandate.
• OptumRx: Pharmacy benefit manager owned by UnitedHealth Group, serving employer, health-plan, and government-program clients. Performs PBM functions directly analogous to PBS administration at large commercial scale, including specialty pharmacy and home delivery.
• Veterans Health Administration — Pharmacy Benefits Management Services (VA PBM): Operates the US Veterans Affairs national formulary and pharmacy benefits program for ~9M enrolled veterans. A government-run PBM analog with statutory authority, similar formulary management philosophy, and government-only funding model — comparable to PBS in mandate and structure, not geography.

Direct peers

• PHARMAC (New Zealand): New Zealand's national pharmaceutical management agency, which negotiates and subsidises prescription medicines for the entire population. Operates the closest functional analog to PBS — a single government agency managing a national formulary and pricing under a statutory mandate — but for a smaller population.
• NHS Business Services Authority (NHS BSA) — Prescription Services: Administers the NHS prescription subsidy scheme in England, processing prescriptions and reimbursing community pharmacies under the national Drug Tariff. Operates effectively as the UK's PBM-equivalent for the NHS, with comparable formulary, co-payment, and exemption logic.

Regional players

• GKV-Spitzenverband (National Association of Statutory Health Insurance Funds): Central association of Germany's statutory health insurance funds, which collectively negotiate and reimburse prescription medicines on behalf of ~73M insured Germans. Performs a national formulary and pricing function analogous to PBS but within Germany's multi-payer SHI system.
• Ministry of Health, Labour and Welfare (MHLW) — Japan NHI Drug Pricing: Japanese government body that sets national health insurance drug prices and manages the reimbursement list for Japan's universal health insurance system. Performs the national price-setting and listing function PBS does, but within a different delivery model and geography.
• Health Canada / Patented Medicine Prices Review Board (PMPRB): Canadian federal body that regulates patented medicine prices and supports the federal/provincial drug subsidy frameworks. Comparable to PBAC's pricing-review role within PBS, but Canada lacks a single national formulary on the PBS model, making it a partial analog.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaceutical Benefits Scheme